Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Retained Earnings (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Retained Earnings for 9 consecutive years, with -$2.1 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 33.3% to -$2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 billion through Dec 2025, down 33.3% year-over-year, with the annual reading at -$2.1 billion for FY2025, 33.3% down from the prior year.
  • Retained Earnings for Q4 2025 was -$2.1 billion at Denali Therapeutics, down from -$1.9 billion in the prior quarter.
  • The five-year high for Retained Earnings was $5.5 million in Q3 2024, with the low at -$2.1 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$606.1 million, with a median of -$248.7 million recorded in 2021.
  • Peak annual rise in Retained Earnings hit 949.31% in 2024, while the deepest fall reached 239444.32% in 2024.
  • Over 5 years, Retained Earnings stood at -$645.0 million in 2021, then surged by 98.93% to -$6.9 million in 2022, then surged by 109.34% to $643000.0 in 2023, then tumbled by 239444.32% to -$1.5 billion in 2024, then tumbled by 33.3% to -$2.1 billion in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$2.1 billion, -$1.9 billion, and -$1.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.